Galecto Biotech

Galecto Presents Updated Clinical Data at ESMO Congress 2023 and Provides Update on Phase 1b/2a GALLANT-1 Trial

Retrieved on: 
星期一, 十月 23, 2023
First grade, NSCLC, Galecto Biotech, ESMO, Providence Portland Medical Center, Congress, European Society for Medical Oncology, Fibrosis, Poster, Clinical trial, Oncology, Rash, RECIST, Lung cancer, Safety, Cancer, Hepatology, Patient, Pharmaceutical industry

The Company believes that GALLANT-1 is the first clinical trial to show that combining an oral galectin-3 inhibitor with a checkpoint inhibitor may enhance the effect of checkpoint inhibitors.

Key Points: 
  • The Company believes that GALLANT-1 is the first clinical trial to show that combining an oral galectin-3 inhibitor with a checkpoint inhibitor may enhance the effect of checkpoint inhibitors.
  • Importantly, these skin rashes were not observed at the recommended Phase 2 dose level of 100 mg GB1211 twice daily.
  • Galecto will continue to supply GB1211 100 mg for the upcoming investigator-initiated Phase 2 trial at Providence Portland Medical Center’s Earle A. Chiles Research Institute (EACRI).
  • Following the poster presentation at the ESMO Congress, the poster will be available on the Scientific Conferences page of Galecto’s investor relations website at https://ir.galecto.com/news-and-events/scientific-events .

The Multiple Myeloma Research Foundation (MMRF) Names Stephanie Oestreich, Ph.D., MPA, as Managing Director of the Myeloma Investment Fund (MIF)

Retrieved on: 
星期四, 十月 5, 2023
Biotechnology, Health, Other Health, Pharmaceutical, Other Philanthropy, Philanthropy, Oncology, Other Science, Research, General Health, Fund Raising, Health Technology, Foundation, Science, RA, John F. Kennedy High School, Faculty, Business, Drug development, ARCH Venture Partners, Multiple myeloma, Multiple Myeloma Research Foundation, Harvard University, Novartis, American Business Council Nigeria, Arm, Galecto Biotech, Therapy, W20, MMRF, MIT, G20, MPA, Growth, CART, Evotec, Business development, Commercial, Patient, Management, Bruker

The Multiple Myeloma Research Foundation (MMRF) has announced the appointment of Stephanie Oestreich, Ph.D., MPA, as Managing Director of its venture philanthropy subsidiary, the Myeloma Investment Fund (MIF).

Key Points: 
  • The Multiple Myeloma Research Foundation (MMRF) has announced the appointment of Stephanie Oestreich, Ph.D., MPA, as Managing Director of its venture philanthropy subsidiary, the Myeloma Investment Fund (MIF).
  • In this role, Dr. Oestreich will lead the overall execution of the MIF’s investment strategy and serve as a member of the MMRF executive leadership team.
  • “We are thrilled to have Dr. Oestreich join our team as Managing Director of the MIF,” said Michael Andreini, President and CEO, the MMRF.
  • “The MIF invests in the most promising companies that are developing innovative clinical assets and technologies that could be transformative for myeloma patients.

Galecto Announces Plans to Explore Strategic Alternatives

Retrieved on: 
星期二, 九月 26, 2023
Galecto Biotech, Workforce, Disclosure, Fibrosis, Cancer, Acquisition, Investment, Retail

Galecto has made the determination to conduct a comprehensive exploration of strategic alternatives focused on maximizing shareholder value.

Key Points: 
  • Galecto has made the determination to conduct a comprehensive exploration of strategic alternatives focused on maximizing shareholder value.
  • As part of this evaluation process, Galecto will explore potential strategic alternatives that may include, but are not limited to, an acquisition, merger, business combination, divestiture of its assets, technologies or capabilities, or other transaction.
  • In connection with the evaluation of strategic alternatives, Galecto plans to implement a restructuring plan that includes reducing its workforce by approximately 29 people, or approximately 70% of its existing headcount.
  • As of June 30, 2023, Galecto’s cash, cash equivalents and investments balance was $52.1 million.

Galecto to Present at Investor Conferences in September

Retrieved on: 
星期四, 八月 31, 2023
Biology, Fibrosis, Cancer, Pharmaceutical industry, Galecto Biotech

BOSTON, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company and world leader in galectin biology focused on the development of novel treatments for fibrosis and cancer, today announced that Hans Schambye, M.D., Ph.D., President and Chief Executive Officer of Galecto, will participate in the following September 2023 conferences.

Key Points: 
  • BOSTON, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company and world leader in galectin biology focused on the development of novel treatments for fibrosis and cancer, today announced that Hans Schambye, M.D., Ph.D., President and Chief Executive Officer of Galecto, will participate in the following September 2023 conferences.
  • Management will also be available for one-on-one meetings.

Galecto Announces Topline Results from Phase 2b GALACTIC-1 Trial of GB0139 for the Treatment of Idiopathic Pulmonary Fibrosis

Retrieved on: 
星期二, 八月 15, 2023
Drug development, NASH, Hepatocellular carcinoma, Liver disease, GGT, COVID-19, Food and Drug Administration, Cancer, Cirrhosis, FVC, Cough, LOXL2, Model for End-Stage Liver Disease, Fibrosis, Vital capacity, Patient, Investment, Periodic breathing, ALT, Mortality, FDA, IPF, Death, AST, Idiopathic pulmonary fibrosis, Food, Safety, Pharmaceutical industry, Medical device, Medicine, MELD, Hepatology, Galecto Biotech

Based on the results of the GALACTIC-1 trial, Galecto plans to discontinue development of GB0139.

Key Points: 
  • Based on the results of the GALACTIC-1 trial, Galecto plans to discontinue development of GB0139.
  • “We are very disappointed that the GALACTIC-1 results do not support the continued development of GB0139 as a new treatment for IPF,” said Hans Schambye, President and Chief Executive Officer of Galecto.
  • The trial compared treatment with the inhaled 3 mg dose of GB0139 to placebo (randomized 2:1) over 52 weeks.
  • Galecto previously announced topline results from its Phase 1b/2a GULLIVER-2 trial of GB1211, its orally available galectin-3 inhibitor, for the treatment of decompensated cirrhosis.

Galecto Reports Second Quarter Operating and Financial Results

Retrieved on: 
星期一, 七月 31, 2023
Molecule, Insurance, Idiopathic disease, Inhalation, Idiopathic pulmonary fibrosis, NASH, ATS, Cancer, NSCLC, Lung cancer, Fibrosis, International Conference on Afghanistan, London (2010), HIV disease progression rates, Patient, Investment, Fatty liver disease, Biology, Poster, Research, FDA, IPF, Cirrhosis, Conference, NIH, Safety, Pharmaceutical industry, Galecto Biotech

BOSTON, July 31, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company and world leader in galectin biology focused on the development of novel treatments for fibrosis and cancer, today announced its operating and financial results for the quarter ended June 30, 2023.

Key Points: 
  • BOSTON, July 31, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company and world leader in galectin biology focused on the development of novel treatments for fibrosis and cancer, today announced its operating and financial results for the quarter ended June 30, 2023.
  • “Galecto has made strong clinical progress in the first half of the year, setting the stage for several important milestones during the rest of 2023.
  • We completed dosing in our Phase 2b GALACTIC-1 trial of GB0139 in idiopathic pulmonary fibrosis in May and topline results are expected in August.
  • The company anticipates that its cash, cash equivalents and investments will be sufficient to fund operating expenses and capital requirements into the second half of 2024.

Galecto Set to Join Russell Microcap® Index

Retrieved on: 
星期二, 六月 20, 2023
Russell Microcap Index, FTSE Russell, Cancer, Russell Indexes, Fibrosis, Biology, Growth, IPF, Idiopathic pulmonary fibrosis, Cryptocurrency, Galecto Biotech

Membership in the Russell Microcap Index, which remains in place for one year, means automatic inclusion in the appropriate growth and value style indexes.

Key Points: 
  • Membership in the Russell Microcap Index, which remains in place for one year, means automatic inclusion in the appropriate growth and value style indexes.
  • FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings and style attributes.
  • “We are pleased to be included in the Russell Microcap Index,” said Hans Schambye, M.D., Ph.D., President and Chief Executive Officer of Galecto.
  • For more information on the Russell Indexes and the Russell U.S. Indexes reconstitution, please visit the FTSE Russell website .

Galecto Completes Dosing in 52-Week Phase 2b GALACTIC-1 Trial of GB0139 in Idiopathic Pulmonary Fibrosis

Retrieved on: 
星期二, 五月 23, 2023
Ruxolitinib, Clinical trial, Bone marrow, Cancer, FVC, Boehringer Ingelheim, Fibrosis, Vital capacity, Patient, Disease, Biology, Liver, Mortality, Cirrhosis, IPF, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Idiopathic pulmonary fibrosis, Food, Safety, Pharmaceutical industry, Galecto Biotech

GALACTIC-1 is a randomized, double-blind, placebo-controlled, parallel-group, multicenter trial being conducted across approximately 100 centers globally.

Key Points: 
  • GALACTIC-1 is a randomized, double-blind, placebo-controlled, parallel-group, multicenter trial being conducted across approximately 100 centers globally.
  • The study is designed to investigate the safety and efficacy of GB0139 in patients with IPF.
  • 144 patients were randomized (2:1) to receive either a 3 mg dose of GB0139 or placebo once daily for 52 weeks.
  • In November 2022, Galecto announced topline results from its Phase 1b/2a trial of GB1211, an orally available galectin-3 inhibitor, in patients with decompensated liver cirrhosis.

Galecto to Present Poster at Upcoming ATS 2023 International Conference

Retrieved on: 
星期三, 五月 17, 2023
Molecule, Idiopathic disease, Idiopathic pulmonary fibrosis, ATS, Cancer, Hyaluronic acid, FVC, Fibrosis, International Conference on Computational Intelligence Methods for Bioinformatics and Biostatistics, Biology, Poster, IPF, Conference, Pharmaceutical industry, Galecto Biotech

BOSTON, May 17, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company and world leader in galectin biology focused on the development of novel treatments for fibrosis and cancer, today announced it will present a poster at the upcoming ATS 2023 International Conference taking place on May 19-24 in Washington, D.C.

Key Points: 
  • BOSTON, May 17, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company and world leader in galectin biology focused on the development of novel treatments for fibrosis and cancer, today announced it will present a poster at the upcoming ATS 2023 International Conference taking place on May 19-24 in Washington, D.C.
  • The poster shows new data on GB0139 in idiopathic pulmonary fibrosis (IPF) patient-derived lung samples.
  • “We are very pleased to present additional data on our small molecule GB0139 at this prestigious conference, as it continues to validate and support our development in IPF,” said Hans Schambye, M.D., Ph.D., President and Chief Executive Officer of Galecto.
  • “We believe the new data from IPF patient-derived lung samples compares well with the approved therapies in this disease model.

Galecto Reports First Quarter Operating and Financial Results

Retrieved on: 
星期五, 四月 28, 2023
Insurance, Ruxolitinib, AACR, RECIST, Bone marrow, Cancer, NSCLC, Lung cancer, LOXL2, Fibrosis, Patient, Investment, Biology, Neoplasm, Research, Idiopathic pulmonary fibrosis, Disease, Pharmaceutical industry, Part, Galecto Biotech

BOSTON, April 28, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company and world leader in galectin biology focused on the development of novel treatments for fibrosis and cancer, today announced its operating and financial results for the quarter ended March 31, 2023.

Key Points: 
  • BOSTON, April 28, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company and world leader in galectin biology focused on the development of novel treatments for fibrosis and cancer, today announced its operating and financial results for the quarter ended March 31, 2023.
  • “Galecto continued to make strong progress with its clinical programs in the first quarter of 2023 and remains on target for several significant milestones this year.
  • Accordingly, Galecto has determined to stop enrolling additional patients in the trial and will continue following the remaining patients.
  • The company anticipates that its cash, cash equivalents and investments will be sufficient to fund operating expenses and capital requirements into the second half of 2024.